Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
Quell Therapeutics, founded by Syncona, has been established with the aim of developing engineered T regulatory (Treg) cell therapies. Quell will seek to utilise the power of Treg cells to advance the
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingDurable & safe resolution of complex autoimmune disease
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease
January 2025 – July 2026 · 3 capturesTransforming lives in immune mediated disease
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease